The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.
Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.
The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.
Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells.
The NCI seeks co-development partners or licensees to further develop the novel ExoVII inhibitor(s) as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial strains.
The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2
Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate.
The National Institutes of Health is seeking commercial partners to co-develop and/or license a heterocyclic scaffold for development of therapeutics against Plk1-dependent cancers.